Search - tctmd.com

Displaying 1 - 20 of 176

Sort: Relevancy | Date

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

L.A. McKeown

May 22, 2025

News Daily News

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

Yael L. Maxwell

April 29, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Todd Neale

December 06, 2024

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Todd Neale

September 01, 2024

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

DISCHARGE Data Reassure on Use of CCTA in Older Chest-Pain Patients

Michael O'Riordan

March 04, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

Advertisement

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Scientific Statement Reviews Current Antithrombotic Options in PAD

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

DISCHARGE Data Reassure on Use of CCTA in Older Chest-Pain Patients

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content